Joe La Barge

Paying for Cures

Colleen Rye, Christiana Bardon, Louis DeGennaro, Joe La Barge, Mark Trusheim, Cynthia Verst, Cindy Virst, Mark Trusseimer, Chris Barden, Joe Medina, Eric Schmidt, Lou, Louis Kombolaini, John McWhorter, Tanisha Carino, Martha Minowski

Discussions on the evolution of curative gene therapies analyze the projected surge of over 500 pipeline candidates and the necessary shift from chronic treatment models to one-time cures that disrupt traditional pricing structures. Industry experts highlight innovative financial mechanisms, including outcomes-based rebates and installment payments, designed to navigate complex regulatory hurdles like Medicaid best price rules and FASB accounting volatility while addressing manufacturing costs. Despite significant challenges in social equity and international reimbursement disparities, the consensus suggests that historical precedents and market-driven competition will ultimately sustain a system capable of integrating these high-cost, durable medical breakthroughs.